Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells

Katerina Dvorakova, Claire M. Payne, Terry H Landowski, Margaret E Tome, Daniel S. Halperin, Robert T Dorr

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Imexon is a new antitumor agent with high activity in multiple myeloma. This drug induces apoptosis, oxidative stress and mitochondrial alterations. However, it was unknown whether imexon activates an intrinsic apoptotic pathway that is associated with activation of caspase-9 or an extrinsic pathway that is induced by receptor-mediated signals such as Fas ligand characterized by caspase-8 activation. In addition, we wanted to investigate the effect of imexon on Bcl-2 family proteins. In RPMI8226 myeloma cells, imexon activated caspase-9 and -3 in a time- and concentration-dependent manner. In contrast, cleavage of procaspase-8 was observed late and only after exposure to very high concentrations of imexon. Confocal microscopy confirmed that caspase-3 is also activated after treatment with imexon. High imexon concentrations activated caspase-3 and -9 at 12 h, while caspase-8 activation occurred only at 48 h. Imexon cytotoxicity was unchanged in three RPMI8226 cell lines with different levels (low, medium and high) of FAS expression. Similarly, the levels of Bcl-2, Bax and Bcl-xL were unchanged in imexon-treated cells. However, Bcl-xL was translocated to the mitochondria. These data suggest that imexon-induced oxidation activates the intrinsic or mitochondrial pathway of apoptosis, involving cytochrome c release and activation of caspase-9 and -3.

Original languageEnglish (US)
Pages (from-to)1031-1042
Number of pages12
JournalAnti-Cancer Drugs
Volume13
Issue number10
DOIs
StatePublished - Nov 2002

Fingerprint

Apoptosis
Caspase 9
Caspase 3
Caspase 8
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
Fas Ligand Protein
Cytochromes c
Multiple Myeloma
Confocal Microscopy
Antineoplastic Agents
Mitochondria
Oxidative Stress
Cell Line
Pharmaceutical Preparations
Proteins

Keywords

  • Apoptosis
  • Caspase
  • Imexon
  • Multiple myeloma

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. / Dvorakova, Katerina; Payne, Claire M.; Landowski, Terry H; Tome, Margaret E; Halperin, Daniel S.; Dorr, Robert T.

In: Anti-Cancer Drugs, Vol. 13, No. 10, 11.2002, p. 1031-1042.

Research output: Contribution to journalArticle

Dvorakova, Katerina ; Payne, Claire M. ; Landowski, Terry H ; Tome, Margaret E ; Halperin, Daniel S. ; Dorr, Robert T. / Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. In: Anti-Cancer Drugs. 2002 ; Vol. 13, No. 10. pp. 1031-1042.
@article{9b44c323812c4304bd1040b85120953a,
title = "Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells",
abstract = "Imexon is a new antitumor agent with high activity in multiple myeloma. This drug induces apoptosis, oxidative stress and mitochondrial alterations. However, it was unknown whether imexon activates an intrinsic apoptotic pathway that is associated with activation of caspase-9 or an extrinsic pathway that is induced by receptor-mediated signals such as Fas ligand characterized by caspase-8 activation. In addition, we wanted to investigate the effect of imexon on Bcl-2 family proteins. In RPMI8226 myeloma cells, imexon activated caspase-9 and -3 in a time- and concentration-dependent manner. In contrast, cleavage of procaspase-8 was observed late and only after exposure to very high concentrations of imexon. Confocal microscopy confirmed that caspase-3 is also activated after treatment with imexon. High imexon concentrations activated caspase-3 and -9 at 12 h, while caspase-8 activation occurred only at 48 h. Imexon cytotoxicity was unchanged in three RPMI8226 cell lines with different levels (low, medium and high) of FAS expression. Similarly, the levels of Bcl-2, Bax and Bcl-xL were unchanged in imexon-treated cells. However, Bcl-xL was translocated to the mitochondria. These data suggest that imexon-induced oxidation activates the intrinsic or mitochondrial pathway of apoptosis, involving cytochrome c release and activation of caspase-9 and -3.",
keywords = "Apoptosis, Caspase, Imexon, Multiple myeloma",
author = "Katerina Dvorakova and Payne, {Claire M.} and Landowski, {Terry H} and Tome, {Margaret E} and Halperin, {Daniel S.} and Dorr, {Robert T}",
year = "2002",
month = "11",
doi = "10.1097/00001813-200211000-00007",
language = "English (US)",
volume = "13",
pages = "1031--1042",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells

AU - Dvorakova, Katerina

AU - Payne, Claire M.

AU - Landowski, Terry H

AU - Tome, Margaret E

AU - Halperin, Daniel S.

AU - Dorr, Robert T

PY - 2002/11

Y1 - 2002/11

N2 - Imexon is a new antitumor agent with high activity in multiple myeloma. This drug induces apoptosis, oxidative stress and mitochondrial alterations. However, it was unknown whether imexon activates an intrinsic apoptotic pathway that is associated with activation of caspase-9 or an extrinsic pathway that is induced by receptor-mediated signals such as Fas ligand characterized by caspase-8 activation. In addition, we wanted to investigate the effect of imexon on Bcl-2 family proteins. In RPMI8226 myeloma cells, imexon activated caspase-9 and -3 in a time- and concentration-dependent manner. In contrast, cleavage of procaspase-8 was observed late and only after exposure to very high concentrations of imexon. Confocal microscopy confirmed that caspase-3 is also activated after treatment with imexon. High imexon concentrations activated caspase-3 and -9 at 12 h, while caspase-8 activation occurred only at 48 h. Imexon cytotoxicity was unchanged in three RPMI8226 cell lines with different levels (low, medium and high) of FAS expression. Similarly, the levels of Bcl-2, Bax and Bcl-xL were unchanged in imexon-treated cells. However, Bcl-xL was translocated to the mitochondria. These data suggest that imexon-induced oxidation activates the intrinsic or mitochondrial pathway of apoptosis, involving cytochrome c release and activation of caspase-9 and -3.

AB - Imexon is a new antitumor agent with high activity in multiple myeloma. This drug induces apoptosis, oxidative stress and mitochondrial alterations. However, it was unknown whether imexon activates an intrinsic apoptotic pathway that is associated with activation of caspase-9 or an extrinsic pathway that is induced by receptor-mediated signals such as Fas ligand characterized by caspase-8 activation. In addition, we wanted to investigate the effect of imexon on Bcl-2 family proteins. In RPMI8226 myeloma cells, imexon activated caspase-9 and -3 in a time- and concentration-dependent manner. In contrast, cleavage of procaspase-8 was observed late and only after exposure to very high concentrations of imexon. Confocal microscopy confirmed that caspase-3 is also activated after treatment with imexon. High imexon concentrations activated caspase-3 and -9 at 12 h, while caspase-8 activation occurred only at 48 h. Imexon cytotoxicity was unchanged in three RPMI8226 cell lines with different levels (low, medium and high) of FAS expression. Similarly, the levels of Bcl-2, Bax and Bcl-xL were unchanged in imexon-treated cells. However, Bcl-xL was translocated to the mitochondria. These data suggest that imexon-induced oxidation activates the intrinsic or mitochondrial pathway of apoptosis, involving cytochrome c release and activation of caspase-9 and -3.

KW - Apoptosis

KW - Caspase

KW - Imexon

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=12244256084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244256084&partnerID=8YFLogxK

U2 - 10.1097/00001813-200211000-00007

DO - 10.1097/00001813-200211000-00007

M3 - Article

C2 - 12439337

AN - SCOPUS:12244256084

VL - 13

SP - 1031

EP - 1042

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 10

ER -